Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population

Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	diabetes mellitus personalized medicine dpp-4 inhibitors efficacy prediction evogliptin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/0cda49c2db13461287d49fbf760d288a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0cda49c2db13461287d49fbf760d288a
record_format	dspace
spelling	oai:doaj.org-article:0cda49c2db13461287d49fbf760d288a2021-11-14T09:00:21ZEffectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population2072-03512072-037810.14341/DM9547https://doaj.org/article/0cda49c2db13461287d49fbf760d288a2018-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9547https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and metabolic predictors of better hypoglycemic response to evogliptin. Matherials and methods: We have conducted a retrospective study, based on the data of a randomized clinical trial comparing effectiveness and safety of evogliptin and sitagliptin in Russian and Korean subpopulations. We provide univariate linear regression models for separate subpopulations and a multivariate stepwise regression model for the combined subpopulation. HbA1c change after 24 weeks of evogliptin treatment was a primary endpoint and a dependent variable in the analysis. Results: The decrease of HbA1c after 24 weeks of treatment with evogliptin in Russian subpopulation negatively correlates with triglycerides/HDL level (p = 0,046). In South Korean subpopulation it correlates positively with HbA1c level at baseline (p < 0,0001). In order to increase the statistical power of the analysis the data of both populations were combined. According to the combined data, the decrease of HbA1c after 24 weeks of treatment with evogliptin positively correlates with HbA1c level at baseline (p<0.0001) and log(HOMA-B) (p=0.0042), and it negatively correlates with log(triglycerides/HDL) (p=0.0057), blood phosphorous concentration (p=0.014) and statin treatment (p=0.044). No correlation of HbA1c change at week 24 was observed with body mass index, diabetes duration and blood C-peptide concentration. Patients able to achieve HbA1c<7,0 % had higher HOMA-B (53.22 ± 36.95 и 39.67 ± 24.74, respectively, р=0.033) and were tend to have higher HDL concentration (1.36 ± 0.28 и 1.26 ± 0.26 mmol/l, respectively, р=0.076) and lower triglycerides to HDL ratio (0.87 ± 0.70 и 1.48 ± 0.95, respectively, р=0.079). Conclusion: A patient, who benefits more when treated with evogliptin, has higher HOMA-B, lower triglycerides to HDL ratio and phosphorous concentration in the 1-2 quartiles of the normal range. Triglycerides to HDL ratio is, probably, a specific effectiveness predictor for Russian, but not for Korean subpopulation. These data prove the difference in effectiveness prediction for different drugs of DPP-4 inhibitors group and reveal the need of further investigation.Anna A. MosikianAlina Y. BabenkoYulia A. SevastyanovaRoman V. DraiEvgenij V. ShlyakhtoEndocrinology Research Centrearticlediabetes mellituspersonalized medicinedpp-4 inhibitorsefficacy predictionevogliptinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 5, Pp 333-343 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus personalized medicine dpp-4 inhibitors efficacy prediction evogliptin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus personalized medicine dpp-4 inhibitors efficacy prediction evogliptin Nutritional diseases. Deficiency diseases RC620-627 Anna A. Mosikian Alina Y. Babenko Yulia A. Sevastyanova Roman V. Drai Evgenij V. Shlyakhto Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
description	Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and metabolic predictors of better hypoglycemic response to evogliptin. Matherials and methods: We have conducted a retrospective study, based on the data of a randomized clinical trial comparing effectiveness and safety of evogliptin and sitagliptin in Russian and Korean subpopulations. We provide univariate linear regression models for separate subpopulations and a multivariate stepwise regression model for the combined subpopulation. HbA1c change after 24 weeks of evogliptin treatment was a primary endpoint and a dependent variable in the analysis. Results: The decrease of HbA1c after 24 weeks of treatment with evogliptin in Russian subpopulation negatively correlates with triglycerides/HDL level (p = 0,046). In South Korean subpopulation it correlates positively with HbA1c level at baseline (p < 0,0001). In order to increase the statistical power of the analysis the data of both populations were combined. According to the combined data, the decrease of HbA1c after 24 weeks of treatment with evogliptin positively correlates with HbA1c level at baseline (p<0.0001) and log(HOMA-B) (p=0.0042), and it negatively correlates with log(triglycerides/HDL) (p=0.0057), blood phosphorous concentration (p=0.014) and statin treatment (p=0.044). No correlation of HbA1c change at week 24 was observed with body mass index, diabetes duration and blood C-peptide concentration. Patients able to achieve HbA1c<7,0 % had higher HOMA-B (53.22 ± 36.95 и 39.67 ± 24.74, respectively, р=0.033) and were tend to have higher HDL concentration (1.36 ± 0.28 и 1.26 ± 0.26 mmol/l, respectively, р=0.076) and lower triglycerides to HDL ratio (0.87 ± 0.70 и 1.48 ± 0.95, respectively, р=0.079). Conclusion: A patient, who benefits more when treated with evogliptin, has higher HOMA-B, lower triglycerides to HDL ratio and phosphorous concentration in the 1-2 quartiles of the normal range. Triglycerides to HDL ratio is, probably, a specific effectiveness predictor for Russian, but not for Korean subpopulation. These data prove the difference in effectiveness prediction for different drugs of DPP-4 inhibitors group and reveal the need of further investigation.
format	article
author	Anna A. Mosikian Alina Y. Babenko Yulia A. Sevastyanova Roman V. Drai Evgenij V. Shlyakhto
author_facet	Anna A. Mosikian Alina Y. Babenko Yulia A. Sevastyanova Roman V. Drai Evgenij V. Shlyakhto
author_sort	Anna A. Mosikian
title	Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
title_short	Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
title_full	Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
title_fullStr	Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
title_full_unstemmed	Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
title_sort	effectiveness prediction of evogliptin treatment in type 2 diabetes mellitus in russian-korean population
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/0cda49c2db13461287d49fbf760d288a
work_keys_str_mv	AT annaamosikian effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT alinaybabenko effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT yuliaasevastyanova effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT romanvdrai effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT evgenijvshlyakhto effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation
_version_	1718429509177311232

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population

Ejemplares similares